@RaceOncology1. Are there any accurate mouse models of...

@RaceOncology
1. Are there any accurate mouse models of carfilzomib?
2. According to the Q&A we would have expected carfilzomib to not show efficacy in this mouse model - so why use it to prove out synergy with Bisantrene? It seems to shed doubt on the accuracy of this model to simulate how MM will respond to drugs.
3. The anti-cancer synergy between Bis+Car seems limited after day 26, is this still clinically relevant? Are we just banking on the carfilzomib side of the combo being more efficacious in humans?

4. As per the triangle report we know that we need not only cardio-protection, but anticancer synergy to produce a combo that insurers will pay for. If we don't see a higher degree of anti-cancer synergy, would insurers still pay because it's a reformulation of carfilzomib?